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Background
Quality of life (QoL) in patients treated with sublingual-
immunotherapy (SLIT) is assessed and compared to
QoL in general population aiming to challenge the the-
sis that non-perception of efficacy by the patient is one
of the main causes for poor adherence in SLIT.
Methods
We conducted a non-interventional, cross-sectional and
retrospective quality-of -life- survey including 201
patients treated with SLIT at one pediatric practice in
Germany. Clinical or demographical characteristics of
the examined patients were not interrogated. Patients´
compliance was calculated based on the duration of
active treatment participation. Quality of life was assessed
with the generic SF-12 health survey in German lan-
guage. The items interrogated within the SF-12 health
survey are weighted, added up and transformed to a phy-
sical component score (PCS) and a mental component
score (MCS). The component scores range from 0 to
100, the higher the score the better QoL is perceived.
Results
Patients’ compliance with SLIT between 2009 and 2014
resulted in a continuation of the treatment by 76-82% in
the second and by 60 – 70% in the third year of therapy.
The interrogated patients who have been treated with
SLIT show a PCS-12 of 49,3 (± 7,0) and a MCS-12 of
52,6 (± 7,2). A different study examining the health sta-
tus of the German general population (n=2453) results
in a PCS-12 of 49,6 (± 8,7) and a MCS-12 of 52,3
(± 8,0) [1] . While patients suffering from perennial or
seasonal allergic rhinitis and asthma have significant
lower QoL than their control group [2].These observa-
tions indicate that patients treated with SLIT have a
comparable QoL as the average person in Germany.
This outcome is challenging the common opinion of
studies reasoning poor adherence of SLIT patients in a
non-perception of efficacy.
Conclusions
This study demonstrates that patients’ compliance with
SLIT can be generally high if holistic approaches as
strict monitoring are considered. QoL in patients treated
with SLIT is as good as QoL of the general population.
Poor adherence in SLIT patients cannot be explained by
non-perception of efficacy.
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